In 2022, the stock market experienced a significant decline. This was a challenging time for many investors.
But what if I were to tell you that during this period of financial turmoil, a quantitative trading system was consistently selecting stocks that were experiencing gains of 100%, 200%, and even 300% or more within a few months?
You may find this hard to believe and question my credibility. But this is exactly what my team and I have developed.
Over the past 15 months, we created a quantitative trading model designed to identify the market’s most rapidly growing and explosive stocks on a weekly basis.
We launched this model in August 2022, with high expectations based on our positive back-test results. We believed that it would at least perform better than the market in the second half of the year and generate a profit, even if the overall market continued to decline.
The model, however, exceeded our expectations and achieved even more.
Our Quant Model’s Breakout Success
The stock market did sink in the second half of 2022. From August into the end of the year, the S&P 500 dropped 7%.
But our model was regularly identifying breakout stocks for triple-digit returns in a matter of months.
Its first big win came in early August, when the model triggered a breakout alert on a small-cap biotech by the name of Immunovant (IMVT). The stock had been languishing in no-man’s land for a few months. But our model picked up on some promising price trend signals and showed the stock was on the cusp of a big breakout.
Since then, Immunovant stock has soared 365% in just five months!
That same month, the model also sensed positive price momentum building in another small biotech stock, Terns Pharmaceuticals (TERN). It triggered a breakout alert on that stock in early August, too.
Since then, the stock has surged 385% higher!
It wasn’t just biotech stocks that our model triggered breakout alerts on in August.
Our model also picked up on the huge tailwinds building in the energy sector. And consequently, it triggered a breakout alert on a tiny oil drilling firm – KLX Energy Services (KLXE) – in early August.
In the five months since then, KLX Energy stock has popped 225%!
Fast-forward to mid-October.
At this time, the stock market was breaking down to new bear market lows. Things looked very dour on Wall Street. Yet, our model was sensing positive price action on a virtually unheard-of biotech by the name of GlycoMimetics (GLYC).
Around the same week that the stock market was plunging to new yearly lows, our model triggered a breakout alert on GlycoMimetics stock.
Since then, GLYC has soared, rising by nearly 360% in just three months!
Most recently, our model identified positive price momentum building in penny fintech stock AppTech Payments (APCX). It triggered a breakout alert on that stock.
A month later, it has more than tripled!
Breakout Stock: Cabaletta Bio (CABA)
Cabaletta Bio (CABA) is a biotechnology company focused on developing and commercializing novel therapies for patients with autoimmune diseases. The company’s CABA platform comprises Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Cabaletta’s own Chimeric AutoAntibody Receptor T (CAART) cells, and is potentially applicable to many autoimmune diseases, such as the treatment of pemphigus vulgaris, a rare autoimmune skin disorder. The company recently announced that it’s exploring an Investigational New Drug (IND) application for CABA-201 in the first half of 2023, and that it expects to have initial clinical data by the same time next year.
One of Cabaletta’s key strengths is its unique approach to treating autoimmune diseases. CABA-201 targets a specific protein that plays a key role in T-cell activation, which is a novel approach compared to traditional therapies that target the entire immune system. This targeted approach has the potential to provide greater efficacy and fewer side effects for patients.
The autoimmune disease market is a large and growing market, with a high unmet medical need. If Cabaletta is successful in developing and commercializing CABA-201, it could become a major player in this space. However, as with any biotech company, there is a high degree of risk and uncertainty involved in the development and commercialization of new therapies.
Overall, Cabaletta Bio is a promising biotechnology company with a strong management team, a unique approach to treating autoimmune diseases and strategic partnerships with leading pharmaceutical companies. It’s worth monitoring the company’s clinical trial results and regulatory approvals, as they will be key drivers of the company’s future success.
Why Our System Flagged CABA
In late 2021, shares of CABA underwent a freefall that lasted well into the fall of 2022 – this was a particularly nasty Stage-4 decline. All told, Cabaletta stock collapsed by more than 95%!
Ordinarily, a stock will go into a Stage-1 consolidation period after a Stage-4 decline, but due to such a severe downturn, CABA stock exploded into a V-shaped rally in October 2022. This sudden Stage-2 breakout happened on the back of strong earnings and an improved business outlook.
V-shaped rallies are tricky because they can often result in false breakouts. We typically look for a long period of “basing” before a stock goes into rally mode, but in this case, CABA’s Stage-2 breakout trend is clearly established. As such, it shows a steep, well-tested support line from this past fall.
Importantly, the bullishness since last fall has come on sustained, strong volume, which means this rally could have legs.
Now, let’s take a look at CABA’s same chart but without the stage trend lines, while adding in CABA’s moving averages.
Like yesterday’s breakout stock, we’re seeing a beautiful technical picture with moving averages lined up in waterfalling fashion. That is, the 50-day moving average (MA) is on top of the 100-day MA, which is on top of the 200-day MA.
Because of its rocket-like rally, CABA hasn’t yet established support at any of its moving averages. Despite the overwhelming strength, CABA’s relative strength index (RSI) levels have eased off in recent weeks, which allows it even more room to continue climbing higher.
Big Winners in Breakout Stocks
As you can see, our quantitative “breakout trading” model has regularly identified breakout stocks that go on to soar hundreds of percent in a matter of months. And it did so even while stocks were suffering through one of their worst bear markets ever.
Now, though, the market tide is starting to turn.
Every single major technical buy signal has been triggered. Price momentum is very positive, and the fundamental factors are starting to meaningfully improve. It increasingly looks like the nasty bear market of 2022 will turn into an explosive bull market in 2023.
We couldn’t think of a better time to use our quantitative trading model to potentially score huge stock market wins, over and over and over again.
If our model regularly identified stocks that went up 100%, 200%, even 300%-plus during one of the worst bear markets in history…
Then, what will it be able to do when that nasty bear market turns into an explosive bull market? Could those 100%, 200%, and 300% winners turn into 800%, 900%, even 1,000%-plus winners?
Our back-tested results show that such huge returns in 2023 are entirely achievable with our quant model.
That’s why you need to get your hands on this breakthrough tech right away. It could be your ultimate tool to score enormous returns in 2023.
So, tomorrow afternoon at 4 p.m. Eastern, I will be hosting an emergency broadcast to unveil this model to the public. I’ll explain how it works and even give away a few stocks that the model is identifying as strong breakout candidates right now. Plus, I’ll even give you the chance to gain access to this model – for a steep discount.
This is a must-attend broadcast for anyone who is serious about making money in the stock market in 2023.